Oxidative stress can help tumors thrive, but one way novel cancer treatments work is by pushing levels to the point where it instead helps them die, scientists report.
Exercise can reduce inflammation in obese people by changing the characteristics of their blood, according to new research published in The Journal of Physiology.
In a world first, Australian researchers have revealed how a deadly fungus and primary cause of life-threatening meningitis exploits the immune system like a 'Trojan Horse' to promote infection.
Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas.
University of Colorado Cancer Center researchers nix leukemia stem cell (LSC) stress-relief pathway to kill LSCs without harming healthy blood stem cells, paving the way for new therapies targeting these most dangerous cancer cells.
People with type 2 diabetes may have an increased risk of having a diagnosis of Parkinson's disease later in life, according to a large study published in the June 13, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology. In addition, the risk may be higher for younger people and those with complications from the disease.
Treatment changes including the advent of targeted and immune therapies have dramatically improved survival for blood cancers, but new report calls for improved evaluation of poorly understood side effects that may develop over time.
Back in the 1970s, a Norwegian family was found to have abnormally high red blood cell counts. Thirty-five years later, researchers succeeded in solving the mystery, thanks to new analytical methods and the latest developments in genetic engineering -- and a chance meeting with a Swiss scientist.
St. Jude Children's Research Hospital found ethanol-lock therapy failed to prevent new or recurring infections in cancer patients with central venous catheters and was associated with increased complications.
AML patients treated with the IDH1 inhibitor ivosidenib show an overall response rate of 41.9 percent, with median progression free survival of 8.2 months. Twenty-four percent of patients achieved a complete response.